Dose-Dependent Effect of Early Antiplatelet Therapy in Acute Ischemic Stroke

This study has been completed.
Sponsor:
Information provided by:
Ruhr University of Bochum
ClinicalTrials.gov Identifier:
NCT01273935
First received: January 10, 2011
Last updated: NA
Last verified: January 2010
History: No changes posted
  Purpose

The aim of this study is to evaluate the low-response prevalence of early antiplatelet therapy and to test the influence of different aspirin dosages in patients with acute ischemic strokes (AIS).


Condition
Test the Efficacy of Antiplatelet Regimes in Acute Stroke

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Dose-Dependent Effect of Early Antiplatelet Therapy in Acute Ischemic Stroke

Resource links provided by NLM:


Further study details as provided by Ruhr University of Bochum:

Primary Outcome Measures:
  • Result of platelet function test [ Designated as safety issue: No ]
    Aggregometry result of antiplatelet therapy


Enrollment: 400
Study Start Date: January 2010
Study Completion Date: December 2010
Groups/Cohorts
Responder
Responder versus Non-Responder as a result of platelet function test
Non-Responder
According to the result of platelet function test

Detailed Description:

Antiplatelet agents are important therapeutic options in treating patients with acute ischemic strokes to prevent recurrent ischemic events or death. The aim of this study was to evaluate the low-response prevalence of early antiplatelet therapy and the influence of different aspirin dosages in patients with acute ischemic strokes (AIS).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients admitted to the stroke unit

Criteria

Inclusion Criteria:

  • suspected acute cerebrovascular ischemic events and patients who were admitted to the stroke unit where antiplatelet therapy was initiated

Exclusion Criteria:

  • severe liver disorders, current gastrointestinal disorders, congestive heart failure, life-threatening malignancies and a personal or family history of bleeding disorders
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01273935

Locations
Germany
Department of Neurology, St. Josef - Hospital, Ruhr-University
Bochum, NRW, Germany, D-44791
Sponsors and Collaborators
Ruhr University of Bochum
Investigators
Principal Investigator: Saskia H Meves, MD Department of Neurology, St. Josef - Hospital, Bochum, Germany
  More Information

No publications provided

Responsible Party: Medical Faculty Ruhr-University Bochum, Dekanat der Medizinischen Fakultät, Forschungsreferat - FoRUM
ClinicalTrials.gov Identifier: NCT01273935     History of Changes
Other Study ID Numbers: MevesASS01
Study First Received: January 10, 2011
Last Updated: January 10, 2011
Health Authority: Germany: Ethics Commission

Keywords provided by Ruhr University of Bochum:
Aspirin, Acute Cerebrovascular Ischemia, Platelet Function

Additional relevant MeSH terms:
Stroke
Cerebral Infarction
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Brain Infarction
Brain Ischemia

ClinicalTrials.gov processed this record on July 24, 2014